Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1887 • 2019 ACR/ARP Annual Meeting
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Richard Moore¹, Tiffany Pan ¹, J. Lee Nelson ² and Christian Lood ¹, ¹University of Washington, Seattle, ²Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Mitochondria are key regulators of metabolism, inflammation and cell death, with mitochondrial dysfunction being associated with several diseases. Though mainly found intracellularly, we recently…
Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Ha-Reum Lee¹, Su-Jin Yoo ², Chan-Geol Park ², Jinhyun Kim ², In Seol Yoo ² and Seong Wook Kang ², ¹Chungnam National University Hospital,, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…
Abstract Number: 2154 • 2019 ACR/ARP Annual Meeting
Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Beatriz Hanaoka¹ and Barbara Gower ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: In patients with rheumatoid arthritis(RA), elevated resting energy expenditure(REE) is associated with rheumatoid cachexia and protein catabolism driven by pro-inflammatory cytokines. IR is also…
Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Maria Chiara Gerardi¹, Laura Andreoli ¹, Antía García-Fernández ², Chiara Bazzani ³, MATTEO FILIPPINI ³, MICAELA FREDI ¹, ROBERTO GORLA ³, Maria Grazia Lazzaroni ⁴, Cecilia Nalli ³, MARCO TAGLIETTI ⁵, SONIA ZATTI ⁶, ANDREA LOJACONO ⁶, Franco Franceschini ¹ and Angela Tincani ¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ²Ramon y Cajal University Hospital, Madrid, Spain, Madrid, Madrid, Spain, ³Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy., Brescia, Italy, ⁵[email protected], Brescia, Italy, ⁶Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…
Abstract Number: 2321 • 2019 ACR/ARP Annual Meeting
Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
Guillaume CLERFOND ¹, Marc VILLEDON DE NAIDE ², Clara ALLEMAND ³, Lucie ULMANN ³, Romain ESCHALIER ³, Martin SOUBRIER ⁴, Bruno Pereira ⁵ and Anne TOURNADRE⁶, ¹CHU de Clermont Ferrand, Clermont Ferrand, ²CHU de Clermont Ferrand, Clermont -Ferrand, France, ³CHU de Clermont Ferrand, Clermont Ferrand, France, ⁴CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ⁵CHU CLERMONT-FERRAND, CLERMONT-FERRAND, France, ⁶CHU de Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Although cardiovascular (CV) risk and mortality are increased in rheumatoid arthritis (RA) and spondyloarthritis (SpA), mechanisms resulting in CV risk excess and stratification are…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Abstract Number: 2365 • 2019 ACR/ARP Annual Meeting
Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Sarah Chen¹, Hemin Lee ², Yinzhu Jin ², Jun Liu ² and Seoyoung C. Kim ², ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Rheumatoid arthritis (RA) patients have a high prevalence of cardiovascular comorbidities including diabetes mellitus (DM). Past studies have suggested a potential beneficial effect of…
Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Ana Goico ¹, Anoka Martis¹, Chistopher Kabir ¹, David Mael ¹ and Shoeb Mohammed ¹, ¹Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…
Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Asmir Vodencarevic ¹, David Simon ², Fabian Hartmann ², Michaela Reiser ², Axel Hueber ², Koray Tascilar ³, Arnd Kleyer ⁴, Marcus Zimmermann-Rittereiser ¹ and Georg Schett⁵, ¹Siemens Healthcare GmbH, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable remission may be feasible in a subset of patients…
Abstract Number: 2874 • 2019 ACR/ARP Annual Meeting
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Ann Madsen ⁴, Jamie Geier ⁴, Jose L. Rivas ⁵, Alina Onofrei ⁶, Christine Barr ⁶, Dimitrios Pappas ⁷, Heather Litman ⁶, Kimberly Dandreo ⁶, Andrea Shapiro ⁸, Carol Connell ⁹ and Arthur Kavanaugh ¹⁰, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer SLU, Madrid, Spain, ⁶Corrona, LLC, Waltham, MA, ⁷Columbia University, New York, NY, ⁸Pfizer Inc, Peapack, NJ, ⁹Pfizer Inc, Groton, CT, ¹⁰University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…
Abstract Number: 37 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis
Yanli Tong¹, Yunqiang Bai ², Yi Zhao ², Yi Liu ² and Yubin Luo ², ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China (People's Republic), ²Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic)
Background/Purpose: Intestinal microbial dysbiosis in patients with rheumatoid arthritis (RA) has raised the interest in studying the role of intestinal microbes in the pathogenesis of…
Abstract Number: 118 • 2019 ACR/ARP Annual Meeting
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients
Maxime Batignes ¹, François Santinon ¹, Marie-Christophe Boissier ², Patrice Decker ¹ and Natacha Bessis¹, ¹Inserm UMR 1125, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²Assistance Publique-Hôpitaux de Paris (AP-HP), Rheumatology Department, Avicenne Hospital, Bobigny, France
Background/Purpose: Regulatory T cells (Treg) are necessary for immune homeostasis but are functionally deficient in inflammatory/autoimmune diseases such as rheumatoid arthritis (RA). On the other…
Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Magdaliz Gorritz ³, Lawrence Chang ², Jing He ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…
Abstract Number: 325 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Elisa Trujillo¹, Antonio Aznar ², Hiurma Sanchez ¹, Marta Hernandez ¹, Alicia García ³ and Maria del mar Trujillo Martin ⁴, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Canarias, Santa cruz de Tenerife, ⁴Servicio de Evaluación y Planificación, Fundación Canaria de Investigación Sanitaria (FUNCANIS) Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)., Santa Cruz de Tenerife, Spain
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a…
Abstract Number: 455 • 2019 ACR/ARP Annual Meeting
Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Laura Martinez-Prat¹, Victor Manuel Martínez Taboada ², Marcos Lopez-Hoyos ³ and Michael Mahler ⁴, ¹Inova Diagnostics, Francisco de Vitoria University, San Diego, CA, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Cantabria, Spain, ⁴Inova Diagnostics, San Diego, CA
Background/Purpose: Over the past years, novel biomarkers have been described in rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD) enzymes. Anti-PAD4 IgG…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].